VC-backed Heptares Therapeutics sold to Japanese trade partner for $400m

518

sold-sale-exit-dealUK biopharmaceutical Heptares Therapeutics, whose backers have included MVM Life Science Partners, Novartis Venture Fund and Takeda Ventures, has been sold to Tokyo-listed pharma company Sosei Group Corporation.

The deal is said to be worth up to $400m.

Heptares is a clinical-stage private technology company focused on creating new medicines to target G protein-coupled receptors, which are said to be involved in many diseases.

The company was founded in 2007 with investment from MVM Life Science Partners and led by co-founders Malcolm Weir and Fiona Marshall.

At the start of this year MVM led an equity financing of up to $10m in portable tablet ultrasound system developer eZono.

Copyright © 2015 AltAssets

Get the latest PE News & Research delivered to your inbox every morning